Literature DB >> 27827317

The Effect of Preservative and Temperature on the Analysis of Circulating Tumor DNA.

Sonya Parpart-Li1, Bjarne Bartlett2,3, Maria Popoli2,3, Vilmos Adleff2, Laura Tucker1, Rebecca Steinberg1, Andrew Georgiadis1, Jill Phallen2, Julie Brahmer2, Nilo Azad2, Ilene Browner2, Daniel Laheru2, Victor E Velculescu2, Mark Sausen1, Luis A Diaz4,3.   

Abstract

Purpose: Analysis of genomic alterations in cell-free DNA (cfDNA) is evolving as an approach to detect, monitor, and genotype malignancies. Methods to separate the liquid from the cellular fraction of whole blood for circulating tumor DNA (ctDNA) analyses have been largely unstudied, although these may be a critical consideration for assay performance.Experimental Design: To evaluate the influence of blood processing on cfDNA and ctDNA quality and yield, we compared the cfDNA levels in serum with those in plasma. Given the limitations of serum for ctDNA analyses, we evaluated the effects of two plasma processing approaches, K2EDTA and Cell-Free DNA BCT (BCT) tubes, on cfDNA and ctDNA recovery. A total of 45 samples from nine patients with cancer were collected in both tube types. Once collected, blood was processed into plasma immediately or kept at room temperature and processed into plasma at 1, 3, 5, or 7 days.
Results: As early as 24 hours after collection, plasma isolated from blood collected in K2EDTA tubes contained an elevated level of cfDNA that increased over time compared with BCT tubes where no significant increase in cfDNA levels was observed. When samples from an additional six patients with cancer, collected in the same manner, were stored at 4°C in K2EDTA tubes over the course of 3 days, total cfDNA and ctDNA levels were comparable between samples collected in BCT tubes. At day 3, there was a trend toward a decrease in ctDNA levels in both tubes that was more pronounced when measuring the mutant allele fraction for cases stored at 4°C in K2EDTA tubes.Conclusions: In summary, methods of blood processing have a strong influence on cfDNA and ctDNA levels and should be a consideration when evaluating ctDNA in peripheral circulation. Clin Cancer Res; 23(10); 2471-7. ©2016 AACR. ©2016 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27827317     DOI: 10.1158/1078-0432.CCR-16-1691

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  56 in total

Review 1.  Circulating cell-free DNA for non-invasive cancer management.

Authors:  Caitlin M Stewart; Dana W Y Tsui
Journal:  Cancer Genet       Date:  2018-03-11

2.  Evaluation of Streck BCT and PAXgene Stabilised Blood Collection Tubes for Cell-Free Circulating DNA Studies in Plasma.

Authors:  Kristina Warton; Nicole L Yuwono; Mark J Cowley; Mark J McCabe; Alwin So; Caroline E Ford
Journal:  Mol Diagn Ther       Date:  2017-10       Impact factor: 4.074

3.  Performance comparison of blood collection tubes as liquid biopsy storage system for minimizing cfDNA contamination from genomic DNA.

Authors:  Yunlong Zhao; Yingjie Li; Ping Chen; Shaojun Li; Jian Luo; Hui Xia
Journal:  J Clin Lab Anal       Date:  2018-09-07       Impact factor: 2.352

Review 4.  Role of liquid biopsy in oncogene-addicted non-small cell lung cancer.

Authors:  Matteo Canale; Luigi Pasini; Giuseppe Bronte; Angelo Delmonte; Paola Cravero; Lucio Crinò; Paola Ulivi
Journal:  Transl Lung Cancer Res       Date:  2019-11

5.  Development of blood-based biomarker tests for early detection of colorectal neoplasia: Influence of blood collection timing and handling procedures.

Authors:  Niels Lech Pedersen; Mathias Mertz Petersen; Jon J Ladd; Paul D Lampe; Robert S Bresalier; Gerard J Davis; Christina Demuth; Sarah Ø Jensen; Claus L Andersen; Linnea Ferm; Ib J Christensen; Hans J Nielsen
Journal:  Clin Chim Acta       Date:  2020-04-06       Impact factor: 3.786

Review 6.  Understanding preanalytical variables and their effects on clinical biomarkers of oncology and immunotherapy.

Authors:  Lokesh Agrawal; Kelly B Engel; Sarah R Greytak; Helen M Moore
Journal:  Semin Cancer Biol       Date:  2017-12-16       Impact factor: 15.707

7.  Molecular Med TRI-CON, 11-16 February 2018, San Francisco, USA.

Authors:  Alison Fitches
Journal:  Mol Diagn Ther       Date:  2018-04       Impact factor: 4.074

8.  Specialized Blood Collection Tubes for Liquid Biopsy: Improving the Pre-analytical Conditions.

Authors:  Laure Sorber; Karen Zwaenepoel; Julie Jacobs; Koen De Winne; Kaat Van Casteren; Elien Augustus; Filip Lardon; Hans Prenen; Marc Peeters; Jan Van Meerbeeck; Geert Roeyen; Christian Rolfo; Patrick Pauwels
Journal:  Mol Diagn Ther       Date:  2020-02       Impact factor: 4.074

9.  Harmonizing Cell-Free DNA Collection and Processing Practices through Evidence-Based Guidance.

Authors:  Sarah R Greytak; Kelly B Engel; Sonya Parpart-Li; Muhammed Murtaza; Abel J Bronkhorst; Mark D Pertile; Helen M Moore
Journal:  Clin Cancer Res       Date:  2020-03-02       Impact factor: 12.531

Review 10.  The value of cell-free DNA for molecular pathology.

Authors:  Caitlin M Stewart; Prachi D Kothari; Florent Mouliere; Richard Mair; Saira Somnay; Ryma Benayed; Ahmet Zehir; Britta Weigelt; Sarah-Jane Dawson; Maria E Arcila; Michael F Berger; Dana Wy Tsui
Journal:  J Pathol       Date:  2018-03-12       Impact factor: 7.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.